Heart failure drug may be ‘cardioprotective strategy’ for high-risk patients with cancer
CHICAGO — Treatment with the heart failure medication sacubitril/valsartan was associated with a lower risk for chemotherapy-related heart damage among high-risk patients with cancer, according to preliminary results of the SARAH trial.Researchers assessed the effects of the angiotensin receptor/neprilysin inhibitor sacubitril/valsartan (Entresto, Novartis) on prevention of cardiotoxicity